How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Coagulation Factors Market
- By Product Type: Factor VIII Concentrates, Factor IX Concentrates, Prothrombin Complex Concentrates (PCC), Activated Factor VII, Fibrinogen Concentrates, Von Willebrand Factor
- By Source: Plasma-Derived Coagulation Factors, Recombinant Coagulation Factors
- By Application: Hemophilia A Treatment, Hemophilia B Treatment, Von Willebrand Disease Management, Surgical Bleeding Control, Trauma-Induced Coagulopathy Management
- By End User: Hospitals, Hemophilia Treatment Centers, Clinics, Home Healthcare Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Factor VIII Concentrates leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 275 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Blood Coagulation Factors Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 6
Source 2
Application 5
End User 4
Companies profiled
CSL Behring
Grifols
Octapharma
Baxter International
Pfizer
Takeda Pharmaceutical Company (Shire)
Novo Nordisk
Sanofi
Sangamo Therapeutics
UniQure
Bioverativ (a Sanofi company)
LFB Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CSL Behring
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Grifols
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Octapharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Baxter International
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Takeda Pharmaceutical Company (Shire)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Novo Nordisk
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sangamo Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →UniQure
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bioverativ (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →LFB Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Haemonetics Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Kedrion Biopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Mitsubishi Tanabe Pharma Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$10,212M by 2033 · 10.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Factor VIII Concentrates54.4
- Factor IX Concentrates15.4
- Prothrombin Complex Concentrates (PCC)6.0
- Activated Factor VII7.5
- Fibrinogen Concentrates8.5
- Von Willebrand Factor8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,478M → $3,508M · 11.4%
Europe$1,030M → $2,372M · 11.0%
Asia Pacific$940.3M → $2,305M · 11.9%
Latin America$582.1M → $1,375M · 11.3%
Middle East and Africa$447.7M → $955.7M · 9.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.822026
10.812027
10.842028
10.852029
10.862030
10.872031
10.892032
10.892033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CSL Behring18.6
- Grifols21.5
- Octapharma6.8
- Baxter International9.0
- Pfizer7.7
- Takeda Pharmaceutical Company (Shire)8.6
- Others27.8
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type33.3%
Source35.7%
Application11.8%
End User19.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.4
- Europe22.6
- Asia Pacific21.9
- Latin America13.1
- Middle East and Africa9.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CSL Behring | 84 | 86 | 96 | 95 | 98 | 74 | 89 |
| Grifols | 78 | 86 | 91 | 76 | 81 | 81 | 82 |
| Octapharma | 76 | 76 | 78 | 83 | 66 | 80 | 77 |
| Baxter International | 80 | 76 | 70 | 69 | 77 | 64 | 73 |
| Pfizer | 60 | 77 | 60 | 74 | 52 | 58 | 64 |
| Takeda Pharmaceutical Company (Shire) | 48 | 54 | 66 | 47 | 71 | 46 | 55 |
| Novo Nordisk | 49 | 58 | 65 | 57 | 63 | 62 | 59 |
| Sanofi | 49 | 49 | 45 | 38 | 39 | 37 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CSL Behring
- Grifols
- Octapharma
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CSL Behring | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Grifols | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Octapharma | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Baxter International | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Pfizer | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| Takeda Pharmaceutical Company (Shire) | − | − | ◐ | − | ◐ | − |
| Novo Nordisk | − | − | − | − | − | − |
| Sanofi | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CSL Behring89
2Grifols82
3Octapharma77
4Baxter International73
5Pfizer64
6Novo Nordisk59
7Takeda Pharmaceutical Company (Shire)55
8Sanofi43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CSL BehringGrifols
Challenger2
Strong scale, closing on the leaders.
OctapharmaBaxter International
Contender2
Focused players with pockets of strength.
PfizerNovo Nordisk
Niche2
Specialists in a single segment or region.
Takeda Pharmaceutical Company (Shire)Sanofi
Go-to-market strategy
Land Product Type in North America, then scale across Blood Coagulation Factors Market — a $53M beachhead inside a $795M market.
Beachhead (SOM)$53Mobtainable near-term
Serviceable (SAM)$318Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Factor VIII Concentrates
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Factor IX Concentrates
Strong fit — clear ROI and a fast path to value.
End user67 fit
Prothrombin Complex Concentrates (PCC)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Coagulation Factors Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation13%
Closed-won6%
$9.0KCAC
$34KLTV
3.7:1LTV : CAC
< 3 moCAC payback
Investment thesis
Blood Coagulation Factors Market is a durable-growth opportunity — $8.45B by 2033, compounding at 8.3%.
TAM · 2025$4.45Btoday
TAM · 2033$8.45Bforecast
CAGR8.3%2027–2033
Cumulative$56.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.45BTotal addressable market
SAM$3.46BServiceable available market
SOM$634MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.45BLarge & growingTAM by 2033 at 8.3% CAGR
$3.46BServiceable nowreachable with today’s model
$634MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.59BBear5.4% CAGR
$8.45BBase8.3% CAGR
$10.8BBull11.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Coagulation Factors Market — a $9.93B market by 2033. Plan: grow share from 6.9% to 11.6%.
Market size · 2033$9.93Btotal addressable
Market CAGR7.7%2027–2033
Target share11.6%from 6.9% today
Revenue ambition$1.15Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 11.6% | On track |
| Revenue | $708M | $1.15B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 29.3% | 38.4% | On track |
| Customer retention | 91.2% | 93.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Source capability
A defensible second engine — invest in Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $124M capacity & capability investment
- Greenlight bolt-on M&A in Source
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Blood Coagulation Factors Market conversation — a $5.58B market you can size, segment and defend in minutes.
Market size · 2033$5.58Btotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,549+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
CSL BehringGrifolsOctapharmaBaxter InternationalPfizerTakeda Pharmaceutical Company (Shire)Novo NordiskSanofi+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Coagulation Factors Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Coagulation Factors Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Coagulation Test Analyzer Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportBlood Collecting Vehicles Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportBlood Collection Devices Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportBlood Collection Equipment Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Collection Manager Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBlood Collection Products for Veterinary Use Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBlood Collection System Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBlood Collection Tube for Noninvasive Prenatal Testing (NIPT) Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Collection Tubes (BCT) Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBlood Collection Tubes and Vials Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Component Extractor Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBlood Conservation Device Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.